Our teams have shown great resilience in this year 2020 and have demonstrated their determination during this final stretch of the development of an innovative product like Estelle. Getting an approval for a new molecule-based product is exceptional, certainly during this year marked by this unprecedented health crisis.
Leon Van Rompay, Chief Executive Officer
The renewal of our Board of Directors last November has given a dynamic momentum to the development of Mithra, which is about to live a pivotal year in its history. With the support of this new governance, we are determined to bring Mithra closer to its many promises.
Patricia Van Dijck, Chairman of the Board
Landmark milestones for lead asset Estelle®
with its first marketing authorizations granted for Canada and the United States. Mithra’s contraceptive pill expanded further its global coverage in key regions like Latin America, 3d largest market worldwide.
Qualification of Estetrol as “New Active Substance”
by the European Medicines Agency. This is the first time in more than 80 years that a new estrogen has appeared in the field of contraceptive solutions.
Launch of the Coronesta Program
to study the effect of Estetrol on the immune, inflammatory and vascular response of patients infected by Covid-19. A new direction demonstrating the potential of Estetrol in indications beyond women’s health.
Commercial launch of the contraceptive hormonal ring Myring®
in several major European countries, representing a total market of more than 60 million euro and nearly 7 million rings per year.
Renewal of the Board of Directors
with the appointment of Patricia van Dijck as Chairman ad interim and Ajit Shetty as Chairman from May 2021.
First Estetrol product approved in the world
Finalization of patient enrolment for the Phase III Program
Covid-19, Perimenopause, Neuroprotection
Coronesta, a new development opportunity in the field of respiratory diseases
Successful commercial launches in Europa
Menopause & Osteoporosis
First launch of a tibolone product in North America
Breast & prostate cancer
Injectable implant based on polymer technology
750,000 rings produced in 2020
Brand new injectable production line
Environmental goal: 3256 additional solar panels
Record cash of
million in cash
to be collected
million of financial
€ 50 million
LDA Capital Limited
€ 65 million
by means of a
€ 20 million
€ 125 million